Abstract
Background
Atrial fibrillation (AF) is an important public health problem in European countries. AF is associated with increased morbidity and mortality, e.g. from heart failure and thromboembolic events. Little data have previously been presented regarding the costs of treatment in patients with AF.
Objective
To estimate total direct and indirect costs in patients with AF in Sweden and Germany, and to identify determinants of total costs.
Methods
A cross-sectional observational study was conducted through surveys to patients and their treating physician in primary care and in hospital outpatient cardiology departments in Sweden and Germany. A total of 922 patients with AF as diagnosed in clinical practice were enrolled and completed the study. Data were collected on medical history, treatment, medical and non-medical resource use, and employment status. Costs (year 2005 values) were calculated by multiplying resources used with prices specific for Sweden and Germany, respectively.
Results
Total annual costs per patient were €7241 in Sweden and €5586 in Germany. Slightly less than 70% of total costs were judged as being AF related in both countries. Costs of AF-related medication were about 2% of total costs in both countries. In a generalized regression model, costs were found to increase with age, but were lower in patients aged >65 years than in those aged ≤65 years, due to the absence of indirect costs in older patients. Costs were highest in patients with persistent AF and lowest in those with permanent AF. Co-morbidities with a significant influence on costs included coronary heart disease, cerebrovascular disease, heart failure and asthma.
Conclusions
Current costs in AF patients are driven by the consequences of AF, while costs for specific treatments for AF are low. The addition of new, effective and safe treatment options could potentially reduce overall healthcare costs in AF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boriani G, Diemberger I, Martignani C, et al. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J 2006; 27(8): 893–4
Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147(1): 121–6
Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90(3): 286–92
Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005; 21(10): 1693–9
Statistical yearbook of Sweden: salaries and wages 2004. Örebro: Statistics Sweden, 2004
Statistisches Bundesamt Deutschland [online]. Available from URL: http://www.destatis.de/presse/deutsch/pm2005/p3010042.htm [Accessed 2010 Aug 20]
Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton (FL): Chapman & Hall, 1993
Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 2007; 10(2): 137–43
Nixon RM, Thompson SG. Parametric modelling of cost data in medical studies. Stat Med 2004; 23(8): 1311–31
Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004 Nov 2; 141(9): 653–61
Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation: results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004 Sep; 25(17): 1542–9
Pietrasik A, Kosior DA, Niewada M, et al. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol 2007 May 16; 118(1): 21–7
Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004 Dec; 10(14 Suppl.): S451–61
Reynolds MR, Essebag V, Zimetbaum P, et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007; 18(6): 628–33
Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(8A): 2–9N
Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1(8532): 526–9
Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74(3): 236–41
Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131(4): 790–5
Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389–96
Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8): 949–53
Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol 2001; 36(7): 775–9
Acknowledgements
The study was sponsored by a research grant from Astra-Zeneca R&D. Åsa Eliasson, Olle Almgren and Nils Edvardsson were employed by AstraZeneca at the time the study was conducted. Linus Jönsson has acted as a consultant to, and received research grants from, AstraZeneca. Data collection was administered by Fast Forward Research, Manchester, UK.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Jönsson, L., Eliasson, Å., Kindblom, J. et al. Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. Appl Health Econ Health Policy 8, 317–325 (2010). https://doi.org/10.2165/11319880-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11319880-000000000-00000